International Assets Investment Management LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS)

International Assets Investment Management LLC bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 187,465 shares of the medical research company's stock, valued at approximately $138,690,000. International Assets Investment Management LLC owned about 0.10% of Exact Sciences at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of EXAS. American Century Companies Inc. increased its stake in Exact Sciences by 16.5% in the first quarter. American Century Companies Inc. now owns 5,760 shares of the medical research company's stock valued at $403,000 after purchasing an additional 817 shares during the period. MetLife Investment Management LLC purchased a new stake in Exact Sciences during the 1st quarter valued at approximately $742,000. Panagora Asset Management Inc. lifted its position in Exact Sciences by 4.6% during the 1st quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company's stock worth $509,000 after acquiring an additional 323 shares during the period. Dimensional Fund Advisors LP lifted its position in Exact Sciences by 13.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 448,640 shares of the medical research company's stock worth $31,377,000 after acquiring an additional 53,454 shares during the period. Finally, Vontobel Holding Ltd. grew its stake in shares of Exact Sciences by 143.5% in the 1st quarter. Vontobel Holding Ltd. now owns 22,230 shares of the medical research company's stock valued at $1,585,000 after purchasing an additional 13,102 shares during the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Exact Sciences

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the firm's stock in a transaction on Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the transaction, the executive vice president now owns 71,787 shares of the company's stock, valued at $5,025,090. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Exact Sciences news, insider Jacob A. Orville sold 2,154 shares of Exact Sciences stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $59.32, for a total value of $127,775.28. Following the completion of the sale, the insider now directly owns 14,324 shares of the company's stock, valued at approximately $849,699.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sarah Condella sold 2,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the transaction, the executive vice president now owns 71,787 shares of the company's stock, valued at $5,025,090. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,113 shares of company stock valued at $4,165,273. 1.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

EXAS has been the subject of several analyst reports. Benchmark upgraded Exact Sciences from a "hold" rating to a "buy" rating and set a $91.00 price target for the company in a research note on Tuesday, January 2nd. TheStreet cut shares of Exact Sciences from a "c-" rating to a "d+" rating in a research note on Monday, February 26th. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Citigroup reissued a "buy" rating and set a $100.00 price target on shares of Exact Sciences in a report on Wednesday. Finally, Guggenheim initiated coverage on Exact Sciences in a report on Thursday, December 14th. They issued a "buy" rating and a $90.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $97.44.

Exact Sciences Price Performance

Shares of Exact Sciences stock traded up $0.07 on Friday, hitting $70.23. The company's stock had a trading volume of 2,025,141 shares, compared to its average volume of 2,778,327. The company has a market capitalization of $12.75 billion, a P/E ratio of -61.61 and a beta of 1.25. Exact Sciences Co. has a 52-week low of $56.05 and a 52-week high of $100.77. The firm has a fifty day moving average price of $62.52 and a 200-day moving average price of $65.05. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. During the same quarter in the prior year, the firm earned ($0.72) earnings per share. The company's revenue for the quarter was up 17.0% compared to the same quarter last year. On average, equities research analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.